Vistin Pharma ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, sales was NOK 207.67 million compared to NOK 102.21 million a year ago. Net income was NOK 4.12 million compared to net loss of NOK 14.91 million a year ago. Basic earnings per share from continuing operations was NOK 0.09 compared to basic loss per share from continuing operations of NOK 0.34 a year ago. Diluted earnings per share from continuing operations was NOK 0.09 compared to diluted loss per share from continuing operations of NOK 0.34 a year ago.